Evidence map›Paper›PMID 30900156›Full record

ArticleJournal of cancer research and clinical oncology2019

Heart myxoma develops oncogenic and metastatic phenotype.

Silvia Cecilia Pacheco-Velázquez, Juan Carlos Gallardo-Pérez, Daniel Díaz, Alhelí Adán-Ladrón de Guevara, Diana Xochiquetzal Robledo-Cadena, Emma Saavedra, Luz Ruiz-Godoy, Luis Roberto Jimenez-Hernández, Jesús Vargas-Barrón, José Luis Aguilar-Ponce and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Frontiers in cardiovascular medicine · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Silvia Cecilia Pacheco-VelázquezDepartamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1. Col Sección XVI, Tlalpan, Mexico City, Mexico.
Juan Carlos Gallardo-PérezDepartamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1. Col Sección XVI, Tlalpan, Mexico City, Mexico.
Daniel DíazCentro de Ciencias de la Complejidad (C3), UNAM, Mexico City, Mexico.
Alhelí Adán-Ladrón de GuevaraDepartamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1. Col Sección XVI, Tlalpan, Mexico City, Mexico.
Diana Xochiquetzal Robledo-CadenaDepartamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1. Col Sección XVI, Tlalpan, Mexico City, Mexico.
Emma SaavedraDepartamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1. Col Sección XVI, Tlalpan, Mexico City, Mexico.
Luz Ruiz-GodoyBanco de Tumores, Instituto Nacional de Cancerología, Mexico City, Mexico.
Luis Roberto Jimenez-HernándezDirección de Investigación, Instituto Nacional de Cardiología, Mexico City, Mexico.
Jesús Vargas-BarrónDirección de Investigación, Instituto Nacional de Cardiología, Mexico City, Mexico.
José Luis Aguilar-PonceBanco de Tumores, Instituto Nacional de Cancerología, Mexico City, Mexico.
Sara Rodríguez-EnríquezDepartamento de Bioquímica, Instituto Nacional de Cardiología, Juan Badiano No. 1. Col Sección XVI, Tlalpan, Mexico City, Mexico. saren960104@hotmail.com.ORCID http://orcid.org/0000-0002-0822-1233
Instituto Nacional de Cardiología · MXInstituto Nacional de Cancerología · MX

Funding

Consejo Nacional de Ciencia y Tecnología 283144
6 · The paper itself

Abstract

purposeHeart myxomas have been frequently considered as benign lesions associated with Carney's complex. However, after surgical removal, myxomas re-emerge causing dysfunctional heart.

methodsTo identify whether cardiac myxomas may develop a metastatic phenotype as occurs in malignant cancers, a profile of several proteins involved in malignancy such as oncogenes (c-MYC, K-RAS and H-RAS), cancer-associated metabolic transcriptional factors (HIF-1α, p53 and PPAR-γ) and epithelial-mesenchymal transition proteins (fibronectin, vimentin, β-catenin, SNAIL and MMP-9) were evaluated in seven samples from a cohort of patients with atrial and ventricular myxomas. The analysis was also performed in: (1) cardiac tissue surrounding the area where myxoma was removed; (2) non-cancer heart tissue (NCHT); and (3) malignant triple negative breast cancer biopsies for comparative purposes.

resultsStatistical analysis applying univariate (Kruskal-Wallis and Dunn's tests) and multivariate analyses (PCA, principal component analysis) revealed that heart myxomas (7-15 times) and myxoma surrounding tissue (22-99 times) vs. NCHT showed high content of c-MYC, p53, vimentin, and HIF-1α, indicating that both myxoma and its surrounding area express oncogenes and malignancy-related proteins as occurs in triple negative breast cancer.

conclusionsBased on ROC (receiver operating characteristics) statistical analysis, c-MYC, HIF-1α, p53, and vimentin may be considered potential biomarkers for malignancy detection in myxoma.

Indexed as

Cell Transformation, NeoplasticPhenotypeAnimalsBiomarkers, TumorEchocardiographyHeart NeoplasmsHumansMyxomaNeoplasm GradingNeoplasm MetastasisNeoplasm StagingOncogenesProteomeProteomicsRatsROC CurveBiomarkers, TumorProteomeHearth myxomaMalignancyMetastasisMetastatic biomarkersOncogenic profile

Identifiers

PMID30900156
PMCPMC11810171
OpenAlexW2923798783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.